Jesus S - Search Results

1

Sonication-Assisted Layer-by-Layer Assembly for Low Solubility Drug Nanoformulation.

Santos AC, Pattekari P, Jesus S, Veiga F, Lvov Y, Ribeiro AJ. Santos AC, et al. Among authors: jesus s. ACS Appl Mater Interfaces. 2015 Jun 10;7(22):11972-83. doi: 10.1021/acsami.5b02002. Epub 2015 May 27. ACS Appl Mater Interfaces. 2015. PMID: 25985366

2

Chitosan-based nanoparticles as a hepatitis B antigen delivery system.

Lebre F, Bento D, Jesus S, Borges O. Lebre F, et al. Among authors: jesus s. Methods Enzymol. 2012;509:127-42. doi: 10.1016/B978-0-12-391858-1.00007-1. Methods Enzymol. 2012. PMID: 22568904

3

Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles.

Jesus S, Soares E, Costa J, Borchard G, Borges O. Jesus S, et al. Int J Pharm. 2016 May 17;504(1-2):59-69. doi: 10.1016/j.ijpharm.2016.03.013. Epub 2016 Mar 11. Int J Pharm. 2016. PMID: 26976502

4

The Inclusion of Chitosan in Poly-ε-caprolactone Nanoparticles: Impact on the Delivery System Characteristics and on the Adsorbed Ovalbumin Secondary Structure.

Jesus S, Fragal EH, Rubira AF, Muniz EC, Valente AJM, Borges O. Jesus S, et al. AAPS PharmSciTech. 2018 Jan;19(1):101-113. doi: 10.1208/s12249-017-0822-1. Epub 2017 Jun 13. AAPS PharmSciTech. 2018. PMID: 28612189

5

Optimization of Chitosan-α-casein Nanoparticles for Improved Gene Delivery: Characterization, Stability, and Transfection Efficiency.

Panão Costa J, Carvalho S, Jesus S, Soares E, Marques AP, Borges O. Panão Costa J, et al. Among authors: jesus s. AAPS PharmSciTech. 2019 Feb 28;20(3):132. doi: 10.1208/s12249-019-1342-y. AAPS PharmSciTech. 2019. PMID: 30820699

6

Safe-by-Design of Glucan Nanoparticles: Size Matters When Assessing the Immunotoxicity.

Colaço M, Marques AP, Jesus S, Duarte A, Borges O. Colaço M, et al. Among authors: jesus s. Chem Res Toxicol. 2020 Apr 20;33(4):915-932. doi: 10.1021/acs.chemrestox.9b00467. Epub 2020 Mar 19. Chem Res Toxicol. 2020. PMID: 32138518

7

Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen.

Jesus S, Soares E, Borchard G, Borges O. Jesus S, et al. Nanomedicine (Lond). 2017 Oct;12(19):2335-2348. doi: 10.2217/nnm-2017-0138. Epub 2017 Sep 4. Nanomedicine (Lond). 2017. PMID: 28868964

8

Adjuvant Activity of Poly-ε-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-γ and IL-17 Production.

Jesus S, Soares E, Borchard G, Borges O. Jesus S, et al. Mol Pharm. 2018 Jan 2;15(1):72-82. doi: 10.1021/acs.molpharmaceut.7b00730. Epub 2017 Dec 7. Mol Pharm. 2018. PMID: 29160080

9

Chitosan:β-glucan particles as a new adjuvant for the hepatitis B antigen.

Soares E, Jesus S, Borges O. Soares E, et al. Among authors: jesus s. Eur J Pharm Biopharm. 2018 Oct;131:33-43. doi: 10.1016/j.ejpb.2018.07.018. Epub 2018 Jul 23. Eur J Pharm Biopharm. 2018. PMID: 30048745

10

Unravelling the Immunotoxicity of Polycaprolactone Nanoparticles-Effects of Polymer Molecular Weight, Hydrolysis, and Blends.

Jesus S, Bernardi N, da Silva J, Colaço M, Panão Costa J, Fonte P, Borges O. Jesus S, et al. Chem Res Toxicol. 2020 Nov 16;33(11):2819-2833. doi: 10.1021/acs.chemrestox.0c00208. Epub 2020 Oct 13. Chem Res Toxicol. 2020. PMID: 33050694

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters